U.S. Drug Patent 8,802,127: Claim Scope, Expiration Risk and Risperidone Implant Patent Landscape

U.S. Patent No. 8,802,127 protects implantable risperidone or 9-OH-risperidone compositions using PLA or PLGA polymers, with defined drug loading, polymer composition and a target time to maximum serum concentration of approximately 20 to 190 days. The patent is materially narrower than a general long-acting risperidone patent because it requires an implantable dosage form and a specific combination of formulation and pharmacokinetic limitations.

The strongest protection is concentrated in claims 1, 18, 19 and 20. Claims 2-17 add narrower composition parameters, including polymer loading, drug loading, PLA:PGA ratios and storage stability.

What does U.S. Patent 8,802,127 protect?

The patent protects two principal categories:

Implantable risperidone compositions.
Methods of implanting those compositions to obtain a defined time to maximum risperidone concentration.

The core claim elements are:

Claim element	Required scope
Dosage form	Implantable composition
Active ingredient	Risperidone or 9-OH-risperidone
Polymer	PLA, optionally with PGA, or PLGA
Polymer content	40%-90% by mass
Drug content	10%-60% by mass
Polymer ratio	PLA:PGA from 50:50 to 100:0 in claim 1; 90:10 to 50:50 in claim 18
Pharmacokinetic result	Time to maximum serum or subject concentration of approximately 20-190 days
Storage limitation	At least 68 days at pH 2.0-7.4 under claim 17
Claimed use	Implantation to obtain the specified risperidone concentration profile

The claims are formulation-specific and result-oriented. A potentially infringing product must satisfy both the structural limitations, such as the polymer and drug concentrations, and the pharmacokinetic limitation unless a court determines that the pharmacokinetic language has a different construction under the intrinsic evidence. (USPTO, 2014a)

How are the independent claims structured?

Claim 1: Broad composition claim

Claim 1 is the principal composition claim. It requires:

risperidone or 9-OH-risperidone;
PLA, with PGA optional;
PLA:PGA molar ratio from 50:50 through 100:0;
drug loading from 10% to 60%;
polymer loading from 40% to 90%;
a time to maximum serum concentration of about 20 to 190 days.

The claim covers pure PLA because the upper ratio endpoint is 100:0. It also covers PLA/PGA blends throughout the stated range.

The claim does not expressly require a particular implant geometry, particle size, molecular weight, manufacturing process, excipient, solvent, implant site or release mechanism. Those omissions broaden the structural scope but increase the importance of the pharmacokinetic limitation.

Claim 18: PLGA-focused composition claim

Claim 18 is independently drafted around a PLGA copolymer. It requires:

PLGA at approximately 40%-90% w/w;
an antipsychotic agent at approximately 10%-60% w/w;
lactide:glycolide ratio from approximately 90:10 to 50:50;
risperidone or 9-OH-risperidone;
time to maximum concentration of approximately 20-190 days.

Claim 18 excludes pure PLA because it requires a PLGA copolymer. It is narrower than claim 1 in polymer identity but retains substantial breadth across loading and copolymer-ratio ranges.

Claims 19 and 20: Method claims

Claims 19 and 20 cover implantation methods rather than compositions standing alone.

Claim 19 requires implanting a risperidone composition using the PLA/PGA parameters of claim 1. Claim 20 requires implantation of the PLGA composition described in claim 18.

These claims may be relevant to:

clinical use of a covered implant;
instructions for use;
sponsor-controlled administration protocols;
clinical testing involving implantation of a qualifying formulation.

Method-claim enforcement generally requires proof that the claimed steps were performed. A product-only theory is more naturally directed to claims 1 or 18.

What formulations are protected by claims 2 through 17?

Claims 2-17 narrow claim 1 but do not create separate independent inventions. The principal subranges are:

Dependent claim	Limitation
2	Polymer about 80% by mass
3	Polymer about 60% by mass
4	Polymer about 55% by mass
5	Polymer about 50% by mass
6	Polymer about 40% by mass
7	Drug about 60% by mass
8	Drug about 50% by mass
9	Drug about 45% by mass
10	Drug about 40% by mass
11	Drug about 30% by mass
12	Drug about 20% by mass
13	PLA:PGA ratio of 60:40
14	PLA:PGA ratio of 75:25
15	PLA:PGA ratio of 85:15
16	PLA:PGA ratio of 90:10
17	Storage stability for at least 68 days at pH 2.0-7.4

Claims 2-12 create specific loading points. Because the independent claim already defines drug and polymer ranges that normally sum to the composition mass, the loading claims may be most relevant where the specification and prosecution history clarify how the percentages were measured.

Claims 13-16 create explicit ratio positions within the broader 50:50 to 100:0 range. Claim 16, at 90:10, overlaps the lower boundary of claim 18.

Claim 17 adds a stability limitation. It is narrower than the principal composition claim and requires evidence of the specified storage performance under the relevant pH conditions.

How broad is the patent’s implant limitation?

The word “implantable” is central to infringement analysis. The claims do not merely cover sustained-release risperidone. They require a composition intended to be implanted in a subject.

Potentially relevant dosage forms include:

solid biodegradable implants;
polymeric rods;
in situ forming depots that become implants after administration;
biodegradable implant matrices;
particulate or molded systems implanted through a delivery device.

The legal treatment of an in situ depot depends on claim construction, product design and the specification. A conventional intramuscular microsphere injection may not satisfy the implant limitation merely because it releases drug over an extended period.

The patent therefore does not automatically cover every long-acting risperidone product. A product using microspheres, an injectable suspension or a non-PLA polymer may fall outside one or more structural limitations.

What is the importance of the 20-to-190-day pharmacokinetic limitation?

The time-to-maximum-concentration limitation is both a source of scope and a potential enforcement constraint.

A competing product may avoid the claim if its validated pharmacokinetic profile has a Tmax below 20 days or above 190 days. Conversely, a product with a covered polymer and loading profile may still require analysis of whether its observed Tmax falls within the claimed range.

The limitation raises several technical issues:

the measurement population;
whether “about” permits statistical variation;
whether serum and plasma measurements are interchangeable;
whether Tmax is measured after the first implant or repeated dosing;
whether the claim requires a fixed result or only capability;
whether the range applies to risperidone, total active moiety or 9-OH-risperidone;
whether fed, fasting, diseased or healthy-subject data are relevant.

Claims 1 and 19 refer to serum concentration or risperidone concentration, while claims 18 and 20 use “maximum concentration” language. The specification and prosecution history would be important in resolving whether these terms are coextensive.

When does U.S. Patent 8,802,127 lose exclusivity?

The patent’s expiration date should be calculated from its effective nonprovisional filing date, adjusted for any patent-term adjustment, patent-term extension or terminal disclaimer. The grant date alone does not determine expiration. Under U.S. law, most utility patents filed after June 8, 1995 generally expire 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments. (35 U.S.C. § 154)

The available claim text does not identify:

the earliest priority application;
the effective U.S. nonprovisional filing date;
patent-term adjustment;
terminal disclaimers;
patent-term extension;
post-grant certificates or reexamination changes.

Accordingly, the patent number and claims alone do not establish a reliable final expiration date. The controlling source is the USPTO patent record and Patent Center transaction history. (USPTO, 2014b)

Exclusivity timeline

Event	Commercial significance
Patent grant	Creates enforceable patent rights, subject to validity and enforceability
NDA approval of a covered product	May support Orange Book listing if FDA listing requirements are satisfied
Patent-term adjustment	Extends the statutory term for qualifying USPTO delay
Patent-term extension	May extend term for regulatory review of an approved product
Expiration	Ends ordinary patent exclusion, subject to other unexpired patents
Post-expiration entry	Still subject to regulatory approval, manufacturing readiness and non-patent barriers

The patent should not be treated as the complete exclusivity position for any risperidone product. A commercial product may be protected by separate formulation, manufacturing, dosing, device, method-of-use or process patents.

What is the Orange Book status of U.S. Patent 8,802,127?

Orange Book relevance depends on whether an approved NDA holder submitted the patent for listing and whether FDA determined that the patent meets applicable listing requirements. A patent directed to an implantable risperidone formulation is not automatically listed against every approved risperidone product.

The relevant products include:

Product	Sponsor or manufacturer	General dosage form	Relevance to Patent 8,802,127
Risperdal Consta	Janssen	Long-acting intramuscular microspheres	No automatic match to an implant claim
Perseris	Indivior	Long-acting subcutaneous depot	Requires product-specific polymer and formulation analysis
Uzedy	Teva	Extended-release injectable suspension	Requires product-specific implant and polymer analysis
Oral risperidone generics	Multiple manufacturers	Tablets or oral solutions	Outside the implant limitation

The FDA Orange Book identifies approved drug products and submitted patent information, but listing is product-specific. (FDA, 2024a) The patent claims supplied here do not establish that Patent 8,802,127 is listed against Risperdal Consta, Perseris, Uzedy or any generic product.

Which companies could challenge the patent through Paragraph IV?

A Paragraph IV certification is relevant only when a generic applicant seeks approval under an abbreviated new drug application referencing an NDA with listed patents. The applicant must certify that the patent is invalid, unenforceable or will not be infringed. A Paragraph IV notice can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework. (21 U.S.C. § 355(j); FDA, 2024b)

The most likely challengers would be:

generic manufacturers developing a covered implant or depot;
manufacturers of long-acting risperidone injections;
contract development and manufacturing organizations with a competing biodegradable polymer platform;
sponsors of 505(b)(2) products using a new delivery system.

Ordinary oral risperidone manufacturers have limited incentive to challenge this patent because their products do not appear to practice the implant limitations. A challenge would become commercially relevant if the patent were listed against a reference product covering a long-acting implant or depot.

No Paragraph IV filing, ANDA litigation, settlement agreement or court judgment can be inferred from the claims alone. Those events must be confirmed through FDA patent-listing records, litigation dockets and company disclosures.

How does this patent compare with competing risperidone products?

Risperdal Consta

Risperdal Consta is a long-acting intramuscular microsphere product. Its dosage form is materially different from a conventional implant. The patent could become relevant only if the product or an authorized generic satisfies the claimed polymer, drug-loading and pharmacokinetic elements.

Perseris

Perseris is a long-acting subcutaneous risperidone depot. Its in situ depot characteristics could make the implant limitation more important than the product’s monthly duration alone. The relevant analysis requires the actual polymer composition, loading percentages and clinical Tmax data.

Uzedy

Uzedy is an extended-release risperidone injectable suspension. Extended release does not by itself establish infringement. A product may avoid the patent through dosage form, polymer identity, drug loading or pharmacokinetic profile.

Oral generic risperidone

Oral products do not contain the claimed implant composition and are outside the principal claim architecture.

How strong is the patent estate?

The patent has meaningful technical scope but appears vulnerable to several validity and enforcement arguments.

Strengths

It combines composition limitations with a pharmacokinetic result.
It covers both risperidone and 9-OH-risperidone.
It spans pure PLA and multiple PLA/PGA ratios.
It covers broad drug and polymer loading ranges.
It includes both composition and method claims.
The 20-to-190-day range may capture multiple sustained-release profiles.

Potential weaknesses

PLA and PLGA implants are established biodegradable drug-delivery technologies.
Risperidone is an established antipsychotic agent.
The claimed ranges may be challenged for anticipation or obviousness if prior art discloses overlapping formulations or predictable release profiles.
Functional Tmax limitations may create proof and enablement issues.
The claims do not identify a narrow molecular-weight range, implant geometry, particle size, manufacturing process or specific release mechanism.
Broad overlapping ranges can face written-description and obviousness attacks depending on the prior art and prosecution record.

The strongest validity position would likely depend on unexpected pharmacokinetic behavior, formulation stability, specific examples and evidence that the claimed ranges were not predictable from known PLA/PLGA depot technology.

What manufacturing and intellectual-property barriers exist?

A competitor may need to design around several independent limitations:

Design-around route	Potential effect
Use a non-PLA/non-PLGA polymer	Avoids the principal polymer limitation
Use an implant with drug loading below 10% or above 60%	May avoid the loading range
Use a PLA:PGA ratio outside the claimed range	May avoid claims 1 and 18
Use a nonimplant injectable system	May avoid the dosage-form limitation
Produce Tmax outside approximately 20-190 days	May avoid the functional limitation
Use an active ingredient other than risperidone or 9-OH-risperidone	Avoids the active-agent limitation
Use a different storage profile	Avoids claim 17 but not necessarily claims 1 or 18

Manufacturing barriers may remain even after a successful patent design-around. Biodegradable implant development requires control of polymer molecular weight, residual solvent, sterilization, drug crystallinity, burst release, degradation products and in vivo release kinetics. These technical requirements can delay a generic or follow-on product independently of patent expiration.

What licensing deals affect Patent 8,802,127?

The claim set does not identify a license, assignment, sublicense or commercialization agreement. Patent ownership and licensing must be separated:

the listed assignee may not be the current owner;
a recorded assignment does not prove that commercial rights were licensed;
an exclusive license may not appear in the patent claims;
a product sponsor may rely on a license from a different patent owner.

No licensing deal should be treated as affecting freedom to operate unless supported by recorded USPTO ownership data, public transaction filings, court documents or sponsor disclosures.

What generic launch scenarios exist?

Scenario 1: No listed patent barrier

A generic applicant could proceed under an ANDA framework if the reference product and listed patents do not create a blocking patent issue. This scenario is more plausible for oral risperidone than for an implantable or depot product.

Scenario 2: Paragraph IV challenge

A sponsor of a competing long-acting product could challenge the patent as invalid, unenforceable or not infringed. The commercial value of the challenge would depend on the patent’s remaining term and whether other patents provide overlapping protection.

Scenario 3: 505(b)(2) development

A sponsor using a new implant or depot may pursue a 505(b)(2) pathway rather than a conventional ANDA. The sponsor would still face patent certification and litigation risks if the product references an NDA with listed patents. (FDA, 2024b)

Scenario 4: Noninfringing product launch

A competitor could use a different polymer, dosage form or release profile. This route may avoid Patent 8,802,127 but would not eliminate regulatory, clinical and manufacturing requirements.

Key Takeaways

U.S. Patent 8,802,127 is directed to implantable risperidone or 9-OH-risperidone compositions.
The principal limitations are PLA or PLGA composition, 10%-60% drug loading, 40%-90% polymer loading and a 20-to-190-day Tmax.
Claims 18 and 20 focus on PLGA and exclude pure PLA.
Claims 19 and 20 add implantation-method protection.
Claim 17 separately protects a storage-stability profile at pH 2.0-7.4.
The patent does not automatically cover every long-acting risperidone injection.
Orange Book relevance is product-specific and cannot be established from the claim text alone.
Biosimilar risk is not the primary issue because risperidone is a small molecule. Generic and 505(b)(2) competition are more relevant.
The patent’s enforceability will depend heavily on the priority chain, prosecution history, prior art and construction of the Tmax limitation.
A reliable expiration date requires the USPTO term record, including priority, patent-term adjustment, terminal disclaimer and any patent-term extension.

FAQs

Does Patent 8,802,127 cover Risperdal Consta?

Not automatically. Risperdal Consta is a long-acting microsphere injection, while the patent claims require an implantable composition with specified PLA or PLGA, loading and pharmacokinetic characteristics.

Can a generic avoid the patent by using a different PLGA ratio?

Potentially. A ratio outside the claimed ranges may avoid literal infringement, but the full formulation and any doctrine-of-equivalents risk would require separate analysis.

Does the patent cover risperidone implants using pure PLA?

Yes. Claim 1 expressly permits a PLA:PGA ratio of 100:0, which corresponds to pure PLA, provided the remaining limitations are satisfied.

Is 9-OH-risperidone treated as a separate protected active ingredient?

Yes. Claims 1 and 18 expressly identify 9-OH-risperidone as an alternative to risperidone. Claims 19 and 20, however, are drafted specifically around risperidone.

Does expiration of Patent 8,802,127 clear all barriers to a risperidone implant?

No. Separate patents may cover the formulation, device, manufacturing process, dosing regimen, delivery system or approved product. Regulatory approval and manufacturing validation would remain separate requirements.

References

U.S. Patent and Trademark Office. (2014a). U.S. Patent No. 8,802,127, claims 1-20.
U.S. Patent and Trademark Office. (2014b). Patent Center: Patent term and prosecution records for U.S. Patent No. 8,802,127. https://patentcenter.uspto.gov/
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Food and Drug Administration. (2024b). Abbreviated new drug application approvals and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
21 U.S.C. § 355(j).
35 U.S.C. § 154.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005206143	⤷ Start Trial
Australia	2006269927	⤷ Start Trial
Canada	2553254	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,802,127